Helix BioPharma Corp. and Moffit Cancer Centre to Present at World Molecular Imaging Congress
September 03 2019 - 7:30AM
Helix BioPharma Corp. (TSX: HBP), (“Helix” or the “Company”), an
immuno-oncology company developing innovative drug candidates for
the prevention and treatment of cancer, is pleased to announce that
they, together with Moffitt Cancer Center (“Moffitt”), will be
presenting a poster entitled “Pharmacodynamics of targeted urease
and checkpoint blockade using Chemical Exchange Saturation Transfer
(“CEST”) and 31P-magnetic resonance spectroscopy (“31P-MRS”).” The
question asked, “Is there a role for hyperpolarized 13C and 15N?”
The poster presentation will take place at the
World Molecular Imaging Congress (“WMIC”), which is taking place at
the Palais des congrès de Montréal in Montréal, Quebec, Canada
(http://www.wmis.org/2019-wmic/) on September 4th through the 7th,
2019.
The presentation describes the use of functional
imaging techniques to measure the effect of L-DOS47 on changing
tumor pH in a pancreatic mouse model. The pH effect can be
measured by CEST MRI using a CT contrast agent iopamidol and by
31P-MRS with 3-aminopropyl phosphate (“3-APP”) as reporting
agent. In both cases, L-DOS47 injection is shown to induce a
localized pH increase at the target tumor. L-DOS47 pH
effect may also have a direct impact on therapy as combined
treatment of L-DOS7 with an anti-PD-1 antibody is more efficacious
than either agent alone in a preliminary round of animal study.
In a separate experiment, high resolution
magnetic resonance spectroscopy of hyperpolarized 13C and 15N urea
was able to show how urease (L-DOS47 enzymatic active component)
breaks down urea directly and induces the pH effect. Both
CEST and hyperpolarization are functional imaging techniques being
studied in clinics to monitor therapeutic purposes.
Helix is exploring the potential application of these techniques to
its L-DOS47 clinical development program.
“I would like to thank and congratulate Dr.
Robert (Bob) Gillies and the Moffitt team,” said Dr. Heman Chao,
Helix’s Chief Executive Officer. “This work complements data that
was presented at the recent American Association for Cancer
Research Annual Meeting 2019, in Atlanta, where the Company
presented a poster presentation on “Improving survival in
pancreatic cancer using Doxorubicin in combination with
L-DOS47”. We look forward to continuing collaboration with
Bob and the team.”
On August 7, 2019 the Company announced that it
had received approval from the U.S. Food and Drug Administration to
initiate a Phase Ib/II study of L-DOS47 and doxorubicin in advanced
metastatic pancreatic cancer.About Helix BioPharma
Corp.
Helix BioPharma Corp. is an immuno-oncology
company specializing in the field of cancer therapy. The company is
actively developing innovative products for the prevention and
treatment of cancer based on its proprietary technologies. Helix’s
product development initiatives include its novel L-DOS47 new drug
candidate and Chimeric Antigen Receptor (“CAR”) based cell
therapies. Helix is currently listed on the TSX under the symbol
“HBP”.
About L-DOS47
L-DOS47 is Helix's first immunoconjugate based
drug candidate in development based on the Company’s novel DOS47
platform technology, which is designed to use an innovative
approach to modify the microenvironmental conditions of cancer
cells in a manner that leads to their destruction.
Investor Relations
Helix BioPharma Corp.9120 Leslie Street, Suite
205Richmond Hill, Ontario, L4B 3J9Tel: 905-841-2300Email:
ir@helixbiopharma.com
Cautionary Statements
This news release may contain forward-looking
statements with respect to Helix, its operations, strategy,
financial performance and condition, including its activities
relating to its drug development program, any anticipated timelines
for the commencement or completion of certain activities such as
raising sufficient capital, merger and acquisition activity,
listing on a U.S. exchange and other information in future periods.
These statements generally can be identified by use of
forward-looking words such as “ambitions”, “potentially
breakthrough”, “should”, “may”, “will”, “expect”, “estimate”,
“anticipate”, “intends”, “believe” or “continue” or the negative
thereof or similar variations. The actual results and performance
of discussed herein could differ materially from those expressed or
implied by such statements. Such statements are qualified in their
entirety by the inherent risks and uncertainties surrounding future
expectations, including: (i) Helix’s ability to operate as a going
concern being dependent mainly on securing sufficient additional
financing in order to fund its ongoing research and development and
other operating activities; (ii) the generally inherent uncertainty
involved in scientific research and drug development and those
specific to Helix’s pre-clinical and clinical development programs
(DOS47, L-DOS47, V-DOS47 and CAR-T); (iii) that any transactions
contemplated herein are completed; and (iv) those risks and
uncertainties affecting Helix as more fully described in Helix’s
most recent Annual Information Form, which is available at
www.sedar.com (together, the “Helix Risk Factors”). Certain
material factors and assumptions are applied in making the
forward-looking statements, including, without limitation, that
sufficient financing will be obtained in a timely manner to allow
Helix to continue operations and implement its clinical trials in
the manner and on the timelines anticipated and that the Helix Risk
Factors will not cause Helix’s actual results or events to differ
materially from the forward-looking statements. These cautionary
statements qualify all such forward-looking statements.
Forward-looking statements and information are
based on the beliefs, assumptions, opinions, plans and expectations
of Helix’s management on the date of this news release, and the
Company does not assume any obligation to update any
forward-looking statement or information should those beliefs,
assumptions, opinions, plans or expectations, or other
circumstances change, except as required by law.
Helix BioPharma (TSX:HBP)
Historical Stock Chart
From May 2024 to Jun 2024
Helix BioPharma (TSX:HBP)
Historical Stock Chart
From Jun 2023 to Jun 2024